What Is Xeris Biopharma Holdings, Inc. (XERS) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Xeris Biopharma Holdings, Inc.'s intrinsic value is estimated at $2.95. Trading at its current price of $8.28, the valuation engine raises significant caution: 10 of 11 models flag downside risk, projecting an average implied return of -64.4%. Notably, PWERM sees the most upside at +9.5% (fair value: $9.06), while EPV is the most conservative at -85.1% ($1.23). The spread between these extremes — +94.6% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About XERS?
11 of 13 models are currently active for XERS. Of these, 1 model suggests upside while 10 models suggest overvaluation. The Bayesian DCF estimates XERS's intrinsic value at $1.96, implying -76.4% downside from the current price. See which stocks rank higher →
How Does XERS Rank in Pharmaceutical Preparations?
Among 469 Pharmaceutical Preparations stocks, XERS ranks #70 by Quality of Company score. CirclFi's QOC score of 6.8/10 evaluates 32 fundamental signals. A score of 6.8 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to healthcare company businesses. For Xeris Biopharma Holdings, Inc., metrics like biosimilar competition timeline provide important context that general-purpose valuation models may underweight.
Is XERS a Value Trap?
CirclFi's Value Trap algorithm assigns XERS a score of 17/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
11 of 13 models are active for Xeris Biopharma Holdings, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Xeris Biopharma Holdings, Inc. scores 6.8 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +94.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every XERS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across XERS's 11 active models, average confidence is 25%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad